Genmab A/S ADR (GMAB)

$18.66 -0.92 (-4.70%)
Market Cap 12.96B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 16.05
Forward PE 13.29
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 1,793,900
Avg Vol 1,565,844
Day's Range N/A - N/A
Shares Out 661.77M
Stochastic %K 43%
Beta 0.98
Analysts Strong Sell
Price Target $33.81

Latest News on GMAB

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Apr 1, 2025, 3:53 PM EDT - 13 hours ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Mar 31, 2025, 11:20 AM EDT - 1 day ago

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

Mar 31, 2025, 8:18 AM EDT - 1 day ago

Transactions in connection with share buy-back program

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

Mar 27, 2025, 2:27 PM EDT - 5 days ago

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Mar 27, 2025, 8:00 AM EDT - 5 days ago

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Mar 25, 2025, 5:28 PM EDT - 7 days ago

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Mar 21, 2025, 11:29 PM EDT - 11 days ago

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Mar 17, 2025, 12:19 PM EDT - 15 days ago

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Mar 14, 2025, 2:30 PM EDT - 18 days ago

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Mar 12, 2025, 2:19 PM EDT - 20 days ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Mar 12, 2025, 2:13 PM EDT - 20 days ago

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S' Annual General Meeting

Mar 12, 2025, 10:23 AM EDT - 20 days ago

Passing of Genmab A/S' Annual General Meeting

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Mar 10, 2025, 10:21 AM EDT - 22 days ago

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Feb 28, 2025, 4:00 PM EST - 4 weeks ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Feb 25, 2025, 2:30 PM EST - 5 weeks ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Feb 20, 2025, 8:00 AM EST - 5 weeks ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Feb 19, 2025, 9:14 AM EST - 5 weeks ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

Feb 18, 2025, 2:25 AM EST - 6 weeks ago

Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

JNJ

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

Feb 14, 2025, 9:32 AM EST - 6 weeks ago

Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

Notice to Convene the Annual General Meeting of Genmab A/S

Feb 13, 2025, 6:00 AM EST - 6 weeks ago

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Feb 12, 2025, 1:14 PM EST - 6 weeks ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Publishes 2024 Annual Report

Feb 12, 2025, 11:01 AM EST - 6 weeks ago

Genmab Publishes 2024 Annual Report

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Jan 23, 2025, 3:08 PM EST - 2 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Jan 22, 2025, 6:23 AM EST - 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 1:56 PM EST - 3 months ago

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Dec 11, 2024, 8:20 AM EST - 3 months ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Dec 9, 2024, 12:00 PM EST - 4 months ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Dec 8, 2024, 11:00 AM EST - 4 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab Is Too Attractive To Ignore

Dec 8, 2024, 8:12 AM EST - 4 months ago

Genmab Is Too Attractive To Ignore

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Dec 7, 2024, 7:00 PM EST - 4 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab to Present at Citi's Global Healthcare Conference

Nov 25, 2024, 11:06 AM EST - 4 months ago

Genmab to Present at Citi's Global Healthcare Conference

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

Nov 9, 2024, 4:38 PM EST - 5 months ago

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

Genmab Announces Financial Results for the First Nine Months of 2024

Nov 6, 2024, 11:02 AM EST - 5 months ago

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab: Looking To Manage My Position Around Q3 Earnings

Nov 6, 2024, 3:17 AM EST - 5 months ago

Genmab: Looking To Manage My Position Around Q3 Earnings

Genmab to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 1:11 PM EST - 5 months ago

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Nov 5, 2024, 12:00 PM EST - 5 months ago

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Oct 15, 2024, 6:25 AM EDT - 6 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Major Shareholder Announcement

Oct 4, 2024, 1:55 PM EDT - 6 months ago

Major Shareholder Announcement

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Sep 15, 2024, 8:45 AM EDT - 7 months ago

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 12:26 PM EDT - 7 months ago

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Aug 23, 2024, 11:55 AM EDT - 7 months ago

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

BNTX

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Aug 19, 2024, 2:00 PM EDT - 8 months ago

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S (GMAB) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 9:48 AM EDT - 8 months ago

Genmab A/S (GMAB) Q2 2024 Earnings Call Transcript

Genmab Announces Financial Results for the First Half of 2024

Aug 8, 2024, 11:03 AM EDT - 8 months ago

Genmab Announces Financial Results for the First Half of 2024

Genmab Updates 2024 Financial Guidance

Aug 8, 2024, 11:00 AM EDT - 8 months ago

Genmab Updates 2024 Financial Guidance

Genmab Takes Full Control of Acasunlimab Development Program

Aug 5, 2024, 5:50 AM EDT - 8 months ago

Genmab Takes Full Control of Acasunlimab Development Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Jul 17, 2024, 6:25 AM EDT - 9 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Jun 28, 2024, 2:00 AM EDT - 9 months ago

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Completion of Share Buy-back Program

Jun 27, 2024, 5:00 PM EDT - 9 months ago

Completion of Share Buy-back Program

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Jun 26, 2024, 7:08 PM EDT - 9 months ago

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)